The kill switch for harmful genes

Biomedical research is like a boot stamping on a biologist's face—for decades. The boot is labeled 'medicinal chemistry.' A biologist may hypothesize that blocking a protein prevents a disease, but crafting a small molecule drug to do so is extremely difficult. Most proteins are 'undruggable,' and drug discovery focuses on a lucky few under the streetlamp.

1. An accidental discovery

The story starts in 1990: scientists added an extra gene to petunias to deepen their color, but the flowers turned white. The culprit was 'small interfering RNA' (siRNA), which 'silences' genes.

RNA is less stable than DNA and often single-stranded; siRNA can recognize and destroy messenger RNA with a matching sequence, stopping protein production. This offers a 'switch' to precisely turn off disease-causing genes.

2. From liver to brain

The first siRNA drug, patisiran, uses lipid nanoparticles to deliver siRNA into liver cells to treat hereditary amyloidosis. But targeting the liver is easier than other organs. Researchers then attached 'address labels' like GalNAc sugar to enable 'naked delivery,' extending dosing intervals to three months.

Now scientists are testing different molecule labels to guide siRNA to kidney, lung, muscle, and even brain—with trials for Alzheimer's disease underway.

3. Future of programmable medicine

siRNA belongs to a class of 'programmable drugs' that directly link biological understanding to treatment. Once delivery is solved, creating a new therapy is as simple as swapping the target sequence, like changing software code.

So far, gene silencing in the liver has been achieved; the same will soon be true for other organs. The gene switch is crossing from science fiction into reality.